Company profile: Oxford Pharmascience
1.1 - Company Overview
Company description
- Provider of proprietary technology platforms to re-develop existing medicines to make them better, safer or easier to take, licensing its technologies and dossiers to a network of partners rather than manufacturing or selling directly to consumers.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Oxford Pharmascience
CohBar
HQ: United States
Website
- Description: Provider of mitochondria-based therapeutics as a clinical-stage biotechnology company developing CB4211 for NASH and obesity, showing reduced liver damage biomarkers and glucose levels; CB5138 analogs in preclinical development for IPF and other fibrotic diseases, reducing lung fibrosis and inflammation; and a Mitochondrial Genome Mining platform to discover therapeutic peptides.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CohBar company profile →
Facet Biotech
HQ: United States
Website
- Description: Provider of biotechnology research and development focused on identifying and developing oncology drugs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Facet Biotech company profile →
Innovation Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies addressing unmet medical needs, developing Brilacidin, a small-molecule drug candidate with immunomodulatory, anti-inflammatory, and antimicrobial properties tested for COVID-19, oral mucositis, inflammatory bowel disease, serious skin infections, and fungal diseases; and BEAMED, an image-guided surgical laser platform under development for treating cancer and epilepsy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Innovation Pharmaceuticals company profile →
Oxford Biomedica
HQ: United Kingdom
Website
- Description: Provider of gene and cell therapy solutions, offering lentiviral LentiVector and AAV platforms for development and manufacturing of gene therapies, plus CDMO services for viral vectors including tech transferred-in execution of client-defined methods, process development, GMP manufacturing, and regulatory support.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oxford Biomedica company profile →
Dyax
HQ: United States
Website
- Description: Provider of biotherapeutics focused on the discovery, development and commercialization for unmet medical needs, with an emphasis on inflammatory and oncology indications; lead product DX-88 approved under the brand name KALBITOR (ecallantide) by the United States Food and Drug.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dyax company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Oxford Pharmascience
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Oxford Pharmascience
2.2 - Growth funds investing in similar companies to Oxford Pharmascience
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Oxford Pharmascience
4.2 - Public trading comparable groups for Oxford Pharmascience
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →